Patient P-01507

Synthetic patientNBL-101 · Day 112 · 55–64 · F · baseline S10Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Improving

Inflammatory state

Stable

Nutritional resilience

Improving

Discontinuation risk

62%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S10
Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 52 GI-04 recommended — GI Support Protocol GI-04
Day 53 Patient accepted — Started GI-04 in the companion
Day 61 GI symptom burden −26% vs expected — GI Support Protocol GI-04
Day 67 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days

Nutritional resilience+7
GI instability-4
Toxicity+4

What helped?

GI Support Protocol GI-04Day 52
Result: symptom burden −26%

LIFE OS recommendation

Dietary Support Protocol NP-02

57%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 26/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 55 and rising
- WearableSleep 5.6 h, below personal baseline
Autonomic recovery ↑45
- WearableResting HR 73 bpm
- WearableShort sleep window
Inflammatory signalling ↑40
- BloodInflammatory load index 58
- WearableHRV 23 ms, trending down
Drug metabolism and exposure ↑20
- BloodToxicity index 52

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.3 · butyrate capacity 26/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 5.8 h
Steps: 4,971
Resting HR: 73 bpm

Daily log: GI score 55, nutritional resilience 46, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01327	47%	S01	GI-04	improved	56
P-01393	47%	S14	GI-04	improved	53
P-01879	47%	S14	SC-12	improved	51
P-01364	46%	S14	GI-04	improved	49
P-01465	46%	S14	NP-02	improved	56
P-01573	46%	S14	GI-04	improved	49
P-01647	46%	S14	GI-04	improved	64
P-01706	46%	S14	GI-04	improved	55
P-01865	46%	S14	NP-02	no change	51
P-01339	45%	S14	GI-04	improved	54
P-01627	45%	S14	GI-04	improved	54
P-01661	45%	S03	GI-04	improved	52